Aeon Global Health Corp. (AGHC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aeon Global Health Corp. (AGHC) trades at $0.00 with AI Score 45/100 (Grade C). Aeon Global Health Corp. provides clinical laboratory testing services and web-based software solutions in the United States. Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for AGHC: AGHC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AGHC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AGHC: the 1 perspectives are evenly split.
How is this calculated? →Aeon Global Health Corp. (AGHC) Healthcare & Pipeline Overview
Aeon Global Health Corp. offers clinical laboratory testing services, including toxicology, pharmacogenomics, and cancer genetic testing, alongside web-based software solutions for healthcare organizations. Operating in the U.S. market, the company aims to enhance clinical workflows and regulatory compliance through its integrated testing and software offerings.
What Is the Investment Thesis for AGHC?
Aeon Global Health Corp. operates in the growing market of clinical laboratory testing and telehealth solutions. The demand for specialized testing services, such as pharmacogenomics and cancer genetic testing, is increasing due to advancements in personalized medicine. The company's web-based software solutions cater to the need for efficient healthcare management and regulatory compliance. However, Aeon Global Health's negative profit margin of -61.7% and lack of dividend payments raise concerns about its financial stability. Investors should closely monitor the company's ability to improve profitability and generate sustainable revenue growth. The pending AI analysis may offer additional insights into the company's prospects.
Based on FMP financials and quantitative analysis
AGHC Key Highlights
- Aeon Global Health Corp. operates in the clinical laboratory testing and web-based software sectors within the healthcare industry.
- The company's laboratory testing services include medical toxicology, DNA pharmacogenomics, and cancer genetic testing.
- Aeon Global Health's web-based software solutions aim to improve healthcare organizations' care coordination and regulatory compliance.
- The company reported a gross margin of 61.3%, indicating a strong ability to control the direct costs associated with its services.
- Aeon Global Health Corp. has a negative profit margin of -61.7%, highlighting potential challenges in achieving profitability.
Who Are AGHC's Competitors?
AGHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AGHC's Key Strengths?
- Specialized testing services in growing areas like pharmacogenomics.
- Integrated software solutions for healthcare management.
- Established presence in the clinical laboratory testing market.
- Gross margin of 61.3% indicates efficient cost management.
What Are AGHC's Weaknesses?
- Negative profit margin of -61.7% raises concerns about financial sustainability.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory compliance and reimbursement rates.
- OTC market listing may limit access to capital.
What Could Drive AGHC Stock Higher?
- Expansion of telehealth services to capitalize on remote patient monitoring trends.
- Strategic partnerships with healthcare providers to expand market reach.
- Increased focus on personalized medicine and targeted therapies.
- Development of new diagnostic tests to expand service offerings.
What Are the Key Risks for AGHC?
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns impacting healthcare spending.
- Intense competition from larger and more established diagnostic companies.
- The company's negative profit margin of -61.7% raises concerns about financial sustainability.
- OTC market listing may limit access to capital.
What Are the Growth Opportunities for AGHC?
- Expansion of Telehealth Services: Aeon Global Health can capitalize on the growing telehealth market by expanding its web-based software solutions. The telehealth market is projected to reach $300 billion by 2028, driven by increasing demand for remote patient monitoring and virtual consultations. By enhancing its telehealth platform with advanced features and integrations, Aeon Global Health can attract more healthcare organizations and generate recurring revenue streams. This expansion can be achieved within the next 2-3 years through strategic partnerships and product development.
- Increased Focus on Personalized Medicine: The company can leverage the growing trend of personalized medicine by expanding its DNA pharmacogenomics and cancer genetic testing services. The personalized medicine market is expected to reach $2.4 trillion by 2030, driven by advancements in genetic sequencing and targeted therapies. By offering comprehensive genetic testing panels and personalized treatment recommendations, Aeon Global Health can cater to the increasing demand for individualized healthcare solutions. This growth opportunity can be realized within the next 3-5 years through strategic collaborations with research institutions and healthcare providers.
- Strategic Partnerships with Healthcare Providers: Aeon Global Health can form strategic partnerships with hospitals, clinics, and physician practices to integrate its testing services and software solutions into their workflows. By collaborating with healthcare providers, the company can gain access to a larger patient base and generate higher testing volumes. These partnerships can also facilitate the adoption of Aeon Global Health's telehealth platform and revenue cycle management solutions. The timeline for establishing these partnerships is within the next 1-2 years, focusing on regional healthcare networks.
- Geographic Expansion within the United States: Aeon Global Health can expand its operations to new geographic markets within the United States. By targeting regions with high demand for specialized testing services and telehealth solutions, the company can increase its revenue and market share. This expansion can be achieved through strategic acquisitions, partnerships, or the establishment of new laboratory facilities. The geographic expansion can be phased over the next 3-5 years, starting with regions that have favorable regulatory environments and demographic trends.
- Development of New Diagnostic Tests: Aeon Global Health can invest in the development of new diagnostic tests to expand its service offerings and cater to emerging healthcare needs. By focusing on innovative testing technologies and biomarkers, the company can differentiate itself from competitors and attract new customers. The development of new diagnostic tests can be a continuous process, with new products launched every 1-2 years based on market demand and technological advancements.
What Opportunities Does AGHC Have?
- Expansion of telehealth services to capitalize on remote patient monitoring trends.
- Increased focus on personalized medicine and targeted therapies.
- Strategic partnerships with healthcare providers to expand market reach.
- Geographic expansion within the United States to new regions.
What Threats Does AGHC Face?
- Intense competition from larger and more established diagnostic companies.
- Changes in healthcare regulations and reimbursement policies.
- Potential for technological obsolescence in testing methods.
- Economic downturns impacting healthcare spending.
What Are AGHC's Competitive Advantages?
- Specialized Testing Services: Offers a range of specialized testing services, including pharmacogenomics and cancer genetic testing, which require specific expertise and technology.
- Integrated Software Solutions: Provides web-based software solutions that complement its testing services, creating a comprehensive offering for healthcare organizations.
- Established Relationships: Has established relationships with healthcare providers and organizations, providing a stable customer base.
What Does AGHC Do?
Aeon Global Health Corp., originally known as Authentidate Holding Corp., rebranded in January 2018 to reflect its focus on the healthcare sector. Headquartered in Gainesville, Georgia, the company operates through two segments: Laboratory Testing Services and Web-Based Software. The Laboratory Testing Services segment provides a range of clinical tests, including medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. These tests analyze blood, urine, or saliva samples to detect drugs, chemicals, and genetic predispositions. The Web-Based Software segment offers software as a service (SaaS) solutions for revenue cycle management and telehealth. These solutions are designed to help healthcare organizations coordinate patient care, streamline administrative and clinical workflows, and ensure compliance with regulatory requirements. Aeon Global Health's integrated approach combines diagnostic testing with software solutions to provide comprehensive support to healthcare providers and patients. The company aims to improve patient outcomes and operational efficiency through its specialized testing services and technology platforms.
What Products and Services Does AGHC Offer?
- Provides medical toxicology testing services to detect the presence of drugs or chemicals.
- Offers DNA pharmacogenomics testing to analyze an individual's genetic response to medications.
- Conducts cancer genetic testing to identify genetic mutations associated with cancer risk.
- Performs molecular biology tests for various diagnostic purposes.
- Provides web-based software as a service (SaaS) for revenue cycle management.
- Offers telehealth products and services to coordinate patient care remotely.
- Helps healthcare organizations enhance administrative and clinical workflows.
- Assists healthcare organizations in complying with regulatory requirements.
How Does AGHC Make Money?
- Generates revenue through laboratory testing services, including toxicology, pharmacogenomics, and genetic testing.
- Earns revenue from web-based software subscriptions and service fees.
- Partners with healthcare organizations to provide integrated testing and software solutions.
What Industry Does AGHC Operate In?
Aeon Global Health Corp. operates within the medical diagnostics and research industry, which is experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market for clinical laboratory testing is expanding, with a focus on specialized tests such as pharmacogenomics and molecular diagnostics. The telehealth market is also growing, driven by the need for remote patient monitoring and efficient healthcare management. Aeon Global Health competes with companies like ARTH, BLEVF, GWHP, MDKM, and MTEM, which offer similar testing services and software solutions. The industry is subject to regulatory oversight and requires compliance with healthcare standards.
Who Are AGHC's Key Customers?
- Healthcare organizations, including hospitals, clinics, and physician practices.
- Patients seeking diagnostic testing services.
- Employers requiring drug testing for employees.
Net sellingInsider Activity
The most recent 12 insider filings for Aeon Global Health Corp. break down as 12 sales and 0 purchases. On net that is roughly 487K shares disposed (about $27K), a signal worth weighing alongside the fundamentals.
AGHC Valuation & Market Position
Relative to its peer group, AGHC's quantitative score of 45/100 is below the peer average of 64/100.
ROE 290%Key Financial Metrics
Return on equity for Aeon Global Health Corp. stands at 290.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.36 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Aeon Global Health Corp. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. AGHC has traded publicly since 1992.
AGHC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized testing services in growing areas like pharmacogenomics.
- Integrated software solutions for healthcare management.
- Established presence in the clinical laboratory testing market.
- Gross margin of 61.3% indicates efficient cost management.
Bear Case
- Negative profit margin of -61.7% raises concerns about financial sustainability.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory compliance and reimbursement rates.
- OTC market listing may limit access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AGHC Latest News
No recent news available for AGHC.
AGHC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AGHC.
Price Targets
Wall Street price target analysis for AGHC.
AGHC MoonshotScore
What does this score mean?
The MoonshotScore rates AGHC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
AGHC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aeon Global Health Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and investors should exercise caution due to the increased risk of fraud and manipulation. Trading on the OTC Other tier typically involves less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, resulting in a higher degree of speculative investment.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the risk of investing in AGHC.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud and Manipulation: OTC Other stocks are more susceptible to fraudulent activities and market manipulation.
- Regulatory Scrutiny: AGHC may face increased regulatory scrutiny due to its OTC listing.
- Shell Risk: The detected shell risk indicates a higher probability of the company being a vehicle for illicit activities.
- Verify the company's management team and their track record.
- Review the company's business plan and revenue model.
- Assess the company's financial condition and cash flow.
- Research the company's regulatory compliance and legal standing.
- Evaluate the company's competitive landscape and market position.
- Check for any red flags related to fraud or manipulation.
- Consult with a financial advisor before investing.
- Established Business Operations: Aeon Global Health Corp. has been operating since 2018, indicating some level of business continuity.
- Specific Industry Focus: The company focuses on clinical laboratory testing and web-based software solutions, suggesting a defined business strategy.
- Headquarters Location: The company is headquartered in Gainesville, Georgia, which provides a physical location for operations.
- Gross Margin: A gross margin of 61.3% suggests the company is able to generate revenue in excess of its direct costs.
What Investors Ask About Aeon Global Health Corp. (AGHC) — Healthcare
What does Aeon Global Health Corp. do?
Aeon Global Health Corp. provides clinical laboratory testing services and web-based software solutions to healthcare organizations in the United States. The company's laboratory testing services include medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. Its web-based software solutions help healthcare organizations coordinate patient care, streamline workflows, and ensure regulatory compliance. Aeon Global Health aims to improve patient outcomes and operational efficiency through its integrated testing and technology platform.
What are the main risks for AGHC?
Aeon Global Health Corp. faces several risks, including intense competition from larger diagnostic companies, changes in healthcare regulations and reimbursement policies, and the potential for technological obsolescence. The company's negative profit margin of -61.7% raises concerns about its financial sustainability. As an OTC-listed company, AGHC also faces risks related to limited liquidity, regulatory scrutiny, and potential for fraud and manipulation. Investors should carefully assess these risks before investing in AGHC.
What are the key factors to evaluate for AGHC?
Aeon Global Health Corp. (AGHC) holds an AI score of 45/100 (low). Not financial advice.
How frequently does AGHC data refresh on this page?
AGHC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AGHC's recent stock price performance?
Aeon Global Health Corp. (AGHC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized testing services in growing areas like pharmacogenomics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AGHC overvalued or undervalued right now?
Valuing Aeon Global Health Corp. (AGHC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AGHC?
Before investing in Aeon Global Health Corp. (AGHC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AGHC to a portfolio?
Key strength of Aeon Global Health Corp. (AGHC): Specialized testing services in growing areas like pharmacogenomics. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- The AI analysis is pending and may provide additional insights.
- OTC market stocks carry higher risks than exchange-listed stocks.